$BHC
Bausch Health Companies Inc. Stock $bhc

$bhc Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-Q Financial Statement

#000088559014000039 Filed on May 09, 2014

Income Statement

Concept	2014 Q1	2013 Q1
Revenue	$1.886B	$1.068B
YoY Change	76.54%	24.8%
Cost Of Revenue	$504.1M	$284.9M
YoY Change	76.94%	27.08%
Gross Profit	$1.382B	$783.5M
YoY Change	76.4%	23.99%
Gross Profit Margin	73.27%	73.33%
Selling, General & Admin	$482.0M	$241.9M
YoY Change	99.26%	36.45%
% of Gross Profit	34.87%	30.87%
Research & Development	$61.30M	$23.80M
YoY Change	157.56%	8.15%
% of Gross Profit	4.44%	3.04%
Depreciation & Amortization	$401.1M	$341.4M
YoY Change	17.49%	58.35%
% of Gross Profit	29.02%	43.57%
Operating Expenses	$543.3M	$265.7M
YoY Change	104.48%	33.32%
Operating Profit	$356.6M	$117.0M
YoY Change	204.79%	90.26%
Interest Expense	-$258.1M	-$150.4M
YoY Change	71.61%	101.88%
% of Operating Profit	-72.38%	-128.55%
Other Income/Expense, Net
YoY Change
Pretax Income	$4.800M	-$54.80M
YoY Change	-108.76%	315.75%
Income Tax	$25.10M	-$27.30M
% Of Pretax Income	522.92%
Net Earnings	-$20.30M	-$27.50M
YoY Change	-26.18%	-115.39%
Net Earnings / Revenue	-1.08%	-2.57%
Basic Earnings Per Share	-$0.07
Diluted Earnings Per Share	-$0.07	-$89.93K
COMMON SHARES
Basic Shares Outstanding	334.9M shares	305.8M shares
Diluted Shares Outstanding	334.9M shares	305.8M shares

Balance Sheet

Concept	2014 Q1	2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$576.0M	$414.0M
YoY Change	39.13%	24.7%
Cash & Equivalents	$576.3M	$413.7M
Short-Term Investments
Other Short-Term Assets	$714.0M	$393.0M
YoY Change	81.68%	84.51%
Inventory	$953.4M	$509.7M
Prepaid Expenses
Receivables	$1.706B	$1.054B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.950B	$2.370B
YoY Change	66.66%	54.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.215B	$453.0M
YoY Change	168.23%	6.08%
Goodwill	$9.916B	$5.165B
YoY Change	91.97%
Intangibles	$12.70B	$9.227B
YoY Change	37.65%
Long-Term Investments
YoY Change
Other Assets	$185.9M	$180.4M
YoY Change	3.04%	47.88%
Total Long-Term Assets	$24.04B	$15.12B
YoY Change	59.03%	25.05%
TOTAL ASSETS
Total Short-Term Assets	$3.950B	$2.370B
Total Long-Term Assets	$24.04B	$15.12B
Total Assets	$27.99B	$17.49B
YoY Change	60.06%	28.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$392.3M	$183.0M
YoY Change	114.35%	17.32%
Accrued Expenses	$1.802B	$1.072B
YoY Change	68.11%	97.35%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$238.9M	$289.7M
YoY Change	-17.53%	99.78%
Total Short-Term Liabilities	$2.563B	$1.646B
YoY Change	55.7%	71.83%
LONG-TERM LIABILITIES
Long-Term Debt	$17.15B	$10.33B
YoY Change	66.04%	50.74%
Other Long-Term Liabilities	$230.0M	$167.1M
YoY Change	37.66%	-72.15%
Total Long-Term Liabilities	$17.38B	$10.49B
YoY Change	65.59%	40.85%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.563B	$1.646B
Total Long-Term Liabilities	$17.38B	$10.49B
Total Liabilities	$22.79B	$13.90B
YoY Change	63.93%	45.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.301B	-$2.424B
YoY Change	36.2%
Common Stock	$8.531B	$6.208B
YoY Change	37.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.090B	$3.587B
YoY Change
Total Liabilities & Shareholders Equity	$27.99B	$17.49B
YoY Change	60.06%	28.39%

Cashflow Statement

Concept	2014 Q1	2013 Q1
OPERATING ACTIVITIES
Net Income	-$20.30M	-$27.50M
YoY Change	-26.18%	-115.39%
Depreciation, Depletion And Amortization	$401.1M	$341.4M
YoY Change	17.49%	58.35%
Cash From Operating Activities	$484.3M	$255.3M
YoY Change	89.7%	52.69%
INVESTING ACTIVITIES
Capital Expenditures	$58.10M	$14.00M
YoY Change	315.0%	25.94%
Acquisitions	$306.3M	$237.6M
YoY Change	28.91%	-12.91%
Other Investing Activities	-$1.400M	-$220.2M
YoY Change	-99.36%	7.21%
Cash From Investing Activities	-$384.1M	-$234.9M
YoY Change	63.52%	7.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$35.00M
YoY Change	-100.0%	-67.81%
Debt Paid & Issued, Net	$433.9M	$430.0M
YoY Change	0.91%	42.0%
Cash From Financing Activities	-$122.7M	-515.9M
YoY Change	-76.22%	-345.2%
NET CHANGE
Cash From Operating Activities	$484.3M	255.3M
Cash From Investing Activities	-$384.1M	-234.9M
Cash From Financing Activities	-$122.7M	-515.9M
Net Change In Cash	-$22.50M	-495.5M
YoY Change	-95.46%	-411.24%
FREE CASH FLOW
Cash From Operating Activities	$484.3M	$255.3M
Capital Expenditures	$58.10M	$14.00M
Free Cash Flow	$426.2M	$241.3M
YoY Change	76.63%	54.6%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-6800000	USD
CY2014Q1	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-27700000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	24800000	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9100000	USD
CY2013Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	4600000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	1200000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	392300000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	327000000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1801500000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1800200000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-132800000	USD
CY2014Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-140000000	USD
CY2014Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	214500000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	228800000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24800000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9100000	USD
CY2013Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9600000	USD
CY2014Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12200000	USD
CY2013Q4	us-gaap	Assets Assets	27970800000	USD
CY2014Q1	us-gaap	Assets Assets	27989000000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	3950100000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3885900000	USD
CY2013Q4	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	15900000	USD
CY2014Q1	us-gaap	Assets Held For Sale Current AssetsHeldForSaleCurrent	29000000	USD
CY2014Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.07
CY2013Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Basic BusinessAcquisitionProFormaEarningsPerShareBasic	-0.25
CY2013Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.25
CY2014Q1	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-0.07
CY2014Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-25100000	USD
CY2013Q1	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-83300000	USD
CY2014Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1889900000	USD
CY2013Q1	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	1917100000	USD
CY2014Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1500000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	916100000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	413700000	USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2013Q1	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	7900000	USD
CY2013Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	2200000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-8900000	USD
CY2013Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	114500000	USD
CY2014Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	119500000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	576300000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	600300000	USD
CY2014Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	333036637	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	333520028	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	333520028	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	333036637	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	8301200000	USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	8316200000	USD
CY2014Q1	us-gaap	Comparability Of Prior Year Financial Data ComparabilityOfPriorYearFinancialData	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Reclassifications </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-104900000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29800000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1500000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-104900000	USD
CY2014Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-28300000	USD
CY2014Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	504100000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	284900000	USD
CY2013Q1	us-gaap	Cost Of Services Licenses And Services CostOfServicesLicensesAndServices	15400000	USD
CY2014Q1	us-gaap	Cost Of Services Licenses And Services CostOfServicesLicensesAndServices	14300000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	951400000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	1529600000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	366900000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	315300000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	20400000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	54900000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	477600000	USD
CY2014Q1	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	504700000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	10800000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	66000000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-6900000	USD
CY2014Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1500000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1329400000	USD
CY2013Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	4600000	USD
CY2014Q1	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2319900000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2319200000	USD
CY2014Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	401100000	USD
CY2013Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	341400000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2014Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	1200000	USD
CY2014Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	1200000	USD
CY2013Q1	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	4600000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3827400000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4177500000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1447000000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1135000000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1270300000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1419500000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	14666700000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	14398800000	USD
CY2014Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10489200000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10571400000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-13400000	USD
CY2013Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1400000	USD
CY2014Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-12600000	USD
CY2013Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1800000	USD
CY2013Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	1900000	USD
CY2014Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2013Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-4500000	USD
CY2014Q1	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	48800000	USD
CY2013Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-21400000	USD
CY2014Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-93700000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	9752100000	USD
CY2014Q1	us-gaap	Goodwill Goodwill	9915900000	USD
CY2014Q1	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	103000000	USD
CY2014Q1	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	45100000	USD
CY2014Q1	us-gaap	Goodwill Translation Adjustments GoodwillTranslationAdjustments	15700000	USD
CY2013Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-54800000	USD
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	4800000	USD
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25100000	USD
CY2013Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-27300000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9200000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	52600000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	30100000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	111700000	USD
CY2014Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	69200000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24900000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22300000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4200000	USD
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2013Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2013Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	16675600000	USD
CY2014Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	16879200000	USD
CY2013Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12848200000	USD
CY2014Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12701700000	USD
CY2014Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	246500000	USD
CY2013Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	155300000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	656300000	USD
CY2014Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	724600000	USD
CY2013Q4	us-gaap	Inventory Gross InventoryGross	982800000	USD
CY2014Q1	us-gaap	Inventory Gross InventoryGross	1060500000	USD
CY2014Q1	us-gaap	Inventory Net InventoryNet	953400000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	883000000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	221800000	USD
CY2014Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	225200000	USD
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	99800000	USD
CY2014Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	107100000	USD
CY2014Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	110700000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	104700000	USD
CY2014Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1800000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1600000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	22737500000	USD
CY2014Q1	us-gaap	Liabilities Liabilities	22785500000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27989000000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27970800000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2512500000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2563000000	USD
CY2014Q1	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	98600000	USD
CY2013Q4	us-gaap	Liability For Uncertain Tax Positions Noncurrent LiabilityForUncertainTaxPositionsNoncurrent	169100000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	17367700000	USD
CY2014Q1	us-gaap	Long Term Debt LongTermDebt	17386900000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	204800000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	238900000	USD
CY2014Q1	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	18400000000	USD
CY2013Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	18400000000	USD
CY2013Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17162900000	USD
CY2014Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17148000000	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	114600000	USD
CY2014Q1	us-gaap	Minority Interest MinorityInterest	113900000	USD
CY2014Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (“OTC”) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over </font><font style="font-family:inherit;font-size:10pt;">100</font><font style="font-family:inherit;font-size:10pt;"> countries. Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act (BCBCA). </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 5, 2013, the Company acquired Bausch & Lomb Holdings Incorporated (“B&L”), pursuant to an Agreement and Plan of Merger, as amended (the “Merger Agreement”) dated May 24, 2013, with B&L surviving as a wholly-owned subsidiary of Valeant Pharmaceuticals International (“Valeant”), a wholly-owned subsidiary of the Company (the “B&L Acquisition”). </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For further information regarding the B&L Acquisition, see note 3 titled “BUSINESS COMBINATIONS”.</font></div></div>
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-502400000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-24000000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-515900000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-122700000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-234900000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-384100000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	484300000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	255300000	USD
CY2014Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	2300000	USD
CY2013Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2014Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22600000	USD
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27500000	USD
CY2014Q1	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	4000000	USD
CY2013Q1	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	37600000	USD
CY2014Q1	us-gaap	Noncontrolling Interest Increase From Business Combination NoncontrollingInterestIncreaseFromBusinessCombination	3300000	USD
CY2014Q1	us-gaap	Number Of Countries In Which Entity Operates NumberOfCountriesInWhichEntityOperates	100	country
CY2014Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segments
CY2014Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segments
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	356600000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	117000000	USD
CY2014Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	185900000	USD
CY2013Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	195500000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2014Q1	us-gaap	Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent	600000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-6600000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-83100000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-7400000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-77400000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-8000000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-77400000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-8000000	USD
CY2014Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	600000	USD
CY2013Q1	us-gaap	Other Income OtherIncome	4500000	USD
CY2014Q1	us-gaap	Other Income OtherIncome	-43300000	USD
CY2014Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	230000000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	160500000	USD
CY2013Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	3700000	USD
CY2014Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-9700000	USD
CY2014Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	43300000	USD
CY2013Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-4500000	USD
CY2014Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	35100000	USD
CY2013Q1	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	29500000	USD
CY2013Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	35000000	USD
CY2014Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2013Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	33300000	USD
CY2014Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	9900000	USD
CY2014Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	27700000	USD
CY2013Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6800000	USD
CY2014Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	306300000	USD
CY2013Q1	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	237600000	USD
CY2014Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	21100000	USD
CY2013Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	700000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58100000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000000	USD
CY2014Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	3300000	USD
CY2013Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0	USD
CY2014Q1	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	169000000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	172000000	USD
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	369900000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	343400000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	360600000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2013Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	9000000	USD
CY2014Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
CY2014Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1400000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	8400000	USD
CY2014Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	1600000	USD
CY2013Q1	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4500000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2600000	USD
CY2014Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3500000	USD
CY2013Q1	us-gaap	Profit Loss ProfitLoss	-27500000	USD
CY2014Q1	us-gaap	Profit Loss ProfitLoss	-20300000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1234200000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1215000000	USD
CY2013Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1676400000	USD
CY2014Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	1706200000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	430000000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	433900000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2600000	USD
CY2014Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	5100000	USD
CY2013Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	1400000	USD
CY2014Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	61300000	USD
CY2013Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	23800000	USD
CY2013Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2014Q1	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	12000000	USD
CY2013Q1	us-gaap	Restructuring Charges RestructuringCharges	49000000	USD
CY2014Q1	us-gaap	Restructuring Charges RestructuringCharges	133600000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3278500000	USD
CY2014Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3301100000	USD
CY2014Q1	us-gaap	Revenues Revenues	1886200000	USD
CY2013Q1	us-gaap	Revenues Revenues	1068400000	USD
CY2014Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1851100000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1038900000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3500000	USD
CY2013Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	35000000	USD
CY2014Q1	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	8700000	USD
CY2014Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	482000000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	241900000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24800000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	9100000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	5118700000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	5089600000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5233300000	USD
CY2014Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5203500000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3717400000	USD
CY2013Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3587000000	USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	300000	USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	46500000	USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	1300000	USD
CY2014Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	146900000	USD
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparing the unaudited consolidated financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the unaudited consolidated financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates and the operating results for the interim periods presented are not necessarily indicative of the results expected for the full year.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company’s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company’s results of operations and financial position could be materially impacted.</font></div></div>
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	305800000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	334900000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	334900000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	305800000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	305800000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	334900000	shares
CY2014Q1	vrx	Acquisition Accounting Adjustment On Inventory Sold AcquisitionAccountingAdjustmentOnInventorySold	5200000	USD
CY2013Q1	vrx	Acquisition Accounting Adjustment On Inventory Sold AcquisitionAccountingAdjustmentOnInventorySold	43200000	USD
CY2013Q1	vrx	Allowances For Losses On Accounts Receivable And Inventories AllowancesForLossesOnAccountsReceivableAndInventories	9000000	USD
CY2014Q1	vrx	Allowances For Losses On Accounts Receivable And Inventories AllowancesForLossesOnAccountsReceivableAndInventories	19600000	USD
CY2014Q1	vrx	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	355200000	USD
CY2013Q1	vrx	Amortization Of Intangible Assets Excluding Amortization Allocated To Revenues Cost Of Good Sold AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold	326200000	USD
CY2014Q1	vrx	Business Acquisition Cost Of Acquired Entity Liabilities Incurred Contingent Consideration At Fair Value BusinessAcquisitionCostOfAcquiredEntityLiabilitiesIncurredContingentConsiderationAtFairValue	21700000	USD
CY2014Q1	vrx	Other Comprehensive Income Unrealized Holding Gain Loss On Equity Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnEquitySecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2013Q1	vrx	Other Comprehensive Income Unrealized Holding Gain Loss On Equity Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnEquitySecuritiesArisingDuringPeriodNetOfTax	5700000	USD
CY2014Q1	vrx	Payment Of Accreted Interest On Contingent Consideration PaymentOfAccretedInterestOnContingentConsideration	700000	USD
CY2013Q1	vrx	Payment Of Accreted Interest On Contingent Consideration PaymentOfAccretedInterestOnContingentConsideration	600000	USD
CY2013Q1	vrx	Business Acquisition Cost Of Acquired Entity Liabilities Incurred Contingent Consideration At Fair Value BusinessAcquisitionCostOfAcquiredEntityLiabilitiesIncurredContingentConsiderationAtFairValue	59100000	USD
CY2014Q1	vrx	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash	8900000	USD
CY2013Q1	vrx	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset Cash BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash	-2200000	USD
CY2014Q1	vrx	Business Combination Contingent Consideration Noncurrent Liability BusinessCombinationContingentConsiderationNoncurrentLiability	257000000	USD
CY2013Q4	vrx	Business Combination Contingent Consideration Noncurrent Liability BusinessCombinationContingentConsiderationNoncurrentLiability	241300000	USD
CY2013Q1	vrx	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	-37400000	USD
CY2014Q1	vrx	Deferred Income Tax Noncash Expense Benefit DeferredIncomeTaxNoncashExpenseBenefit	10000000	USD
CY2014Q1	vrx	Defined Benefit Plan Employer Contribution Maximum Age DefinedBenefitPlanEmployerContributionMaximumAge	P65Y
CY2014Q1	vrx	Highly Liquid Investments Maturity Period HighlyLiquidInvestmentsMaturityPeriod	P3M
CY2014Q1	vrx	Longtermdebt Prepayments Reductionin Principal LongtermdebtPrepaymentsReductioninPrincipal	70300000	USD
CY2014Q1	vrx	Payments Of Contingent Consideration PaymentsOfContingentConsideration	9700000	USD
CY2013Q1	vrx	Payments Of Contingent Consideration PaymentsOfContingentConsideration	21100000	USD
CY2013Q1	vrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	312400000	shares
CY2014Q1	vrx	Potential Weighted Average Number Of Diluted Shares Outstanding PotentialWeightedAverageNumberOfDilutedSharesOutstanding	341500000	shares
CY2014Q1	vrx	Stockholders Equity Before Comprehensive Income Net Of Tax StockholdersEquityBeforeComprehensiveIncomeNetOfTax	5231800000	USD
CY2013Q1	vrx	Stockholders Equity Before Comprehensive Income Net Of Tax StockholdersEquityBeforeComprehensiveIncomeNetOfTax	3691900000	USD
CY2014Q1	vrx	Unrecognized Tax Benefits Including Interest And Penalties UnrecognizedTaxBenefitsIncludingInterestAndPenalties	241000000	USD
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000885590
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	335267871	shares
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	Valeant Pharmaceuticals International, Inc.

Files In Submission

Name	View Source	Status
0000885590-14-000039-index-headers.html	Edgar Link	pending
0000885590-14-000039-index.html	Edgar Link	pending
0000885590-14-000039.txt	Edgar Link	pending
0000885590-14-000039-xbrl.zip	Edgar Link	pending
exhibit101.htm	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
valeantq12014.htm	Edgar Link	pending
vrx-20140331.xml	Edgar Link	completed
vrx-20140331.xsd	Edgar Link	pending
vrx-20140331_cal.xml	Edgar Link	unprocessable
vrx-20140331_def.xml	Edgar Link	unprocessable
vrx-20140331_lab.xml	Edgar Link	unprocessable
vrx-20140331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BHC
Bausch Health Companies Inc. Stock $bhc

2014 Q1 Form 10-Q Financial Statement

#000088559014000039 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BHC Bausch Health Companies Inc. Stock $bhc

2014 Q1 Form 10-Q Financial Statement

#000088559014000039 Filed on May 09, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BHC
Bausch Health Companies Inc. Stock $bhc